TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/25/2024
Back to search
Official data from USPTO
KRAZATI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
06/25/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
08/09/2022
Registration date
09/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/05/2023
Last transaction
06/25/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/13/2022
First use in commerce
12/13/2022
Drawing code
5
Owner type
03
Owner location
San Diego, CA
Examiner
SINGLETON, RUDY
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized term "KRAZATI".
Holders and representatives
Holders
Mirati Therapeutics, Inc.
Representatives
Marilyn F. Kelly Bristol-Myers Squibb Company
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
Class 42
research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Publications
History of USPTO decisions and trademark events.
25 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/25/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/25/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
09/05/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/02/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/01/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/09/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/08/2023
IUAF
USE AMENDMENT FILED
04/19/2023
EISU
TEAS STATEMENT OF USE RECEIVED
04/19/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/07/2023
PUBO
PUBLISHED FOR OPPOSITION
02/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/31/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/31/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/30/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/30/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/29/2022
GNRT
NON-FINAL ACTION E-MAILED
09/29/2022
CNRT
NON-FINAL ACTION WRITTEN
09/29/2022
DOCK
ASSIGNED TO EXAMINER
09/28/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/29/2022
NWAP
NEW APPLICATION ENTERED
08/12/2022
Continuous trademark protection
Get notified about every new filing that threatens KRAZATI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.